{"title":"利用非线性混合效应建模,为准确估算时间积分活动选择基于人群的模型。","authors":"","doi":"10.1016/j.zemedi.2023.01.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Personalized treatment planning in Molecular Radiotherapy (MRT) with accurately determining the absorbed dose is highly desirable. The absorbed dose is calculated based on the Time-Integrated Activity (TIA) and the dose conversion factor. A crucial unresolved issue in MRT dosimetry is which fit function to use for the TIA calculation. A data-driven population-based fitting function selection could help solve this problem. Therefore, this project aims to develop and evaluate a method for accurately determining TIAs in MRT, which performs a Population-Based Model Selection within the framework of the Non-Linear Mixed-Effects (NLME-PBMS) model.</p></div><div><h3>Methods</h3><p>Biokinetic data of a radioligand for the Prostate-Specific Membrane Antigen (PSMA) for cancer treatment were used. Eleven fit functions were derived from various parameterisations of mono-, bi-, and tri-exponential functions. The functions' fixed and random effects parameters were fitted (in the NLME framework) to the biokinetic data of all patients. The goodness of fit was assumed acceptable based on the visual inspection of the fitted curves and the coefficients of variation of the fitted fixed effects. The Akaike weight, the probability that the model is the best among the whole set of considered models, was used to select the fit function most supported by the data from the set of functions with acceptable goodness of fit. NLME-PBMS Model Averaging (MA) was performed with all functions having acceptable goodness of fit. The Root-Mean-Square Error (RMSE) of the calculated TIAs from individual-based model selection (IBMS), a shared-parameter population-based model selection (SP-PBMS) reported in the literature, and the functions from NLME-PBMS method to the TIAs from MA were calculated and analysed. The NLME-PBMS (MA) model was used as the reference as this model considers all relevant functions with corresponding Akaike weights.</p></div><div><h3>Results</h3><p>The function <span><math><mrow><msub><mi>f</mi><mrow><mn>3</mn><mi>a</mi></mrow></msub><mo>=</mo><msub><mi>A</mi><mn>1</mn></msub><msup><mrow><mspace></mspace><mi>e</mi></mrow><mrow><mo>-</mo><mfenced><mrow><msub><mi>λ</mi><mn>1</mn></msub><mo>+</mo><msub><mi>λ</mi><mrow><mi>phys</mi></mrow></msub></mrow></mfenced><mi>t</mi></mrow></msup><mo>+</mo><msub><mi>A</mi><mn>2</mn></msub><msup><mrow><mspace></mspace><mi>e</mi></mrow><mrow><mo>-</mo><mfenced><mrow><msub><mi>λ</mi><mrow><mi>phys</mi></mrow></msub></mrow></mfenced><mi>t</mi></mrow></msup></mrow></math></span> was selected as the function most supported by the data with an Akaike weight of (54 ± 11) %. Visual inspection of the fitted graphs and the RMSE values show that the NLME model selection method has a relatively better or equivalent performance than the IBMS or SP-PBMS methods. The RMSEs of the IBMS, SP-PBMS, and NLME-PBMS (<span><math><msub><mi>f</mi><mrow><mn>3</mn><mi>a</mi></mrow></msub></math></span>) methods are 7.4%, 8.8%, and 2.4%, respectively.</p></div><div><h3>Conclusion</h3><p>A procedure including fitting function selection in a population-based method was developed to determine the best fit function for calculating TIAs in MRT for a given radiopharmaceutical, organ and set of biokinetic data. The technique combines standard practice approaches in pharmacokinetics, i.e. an Akaike-weight-based model selection and the NLME model framework.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0939388923000077/pdfft?md5=74c506ab31c26e269984eefabd8f12a8&pid=1-s2.0-S0939388923000077-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Population-based model selection for an accurate estimation of time-integrated activity using non-linear mixed-effects modelling\",\"authors\":\"\",\"doi\":\"10.1016/j.zemedi.2023.01.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>Personalized treatment planning in Molecular Radiotherapy (MRT) with accurately determining the absorbed dose is highly desirable. The absorbed dose is calculated based on the Time-Integrated Activity (TIA) and the dose conversion factor. A crucial unresolved issue in MRT dosimetry is which fit function to use for the TIA calculation. A data-driven population-based fitting function selection could help solve this problem. Therefore, this project aims to develop and evaluate a method for accurately determining TIAs in MRT, which performs a Population-Based Model Selection within the framework of the Non-Linear Mixed-Effects (NLME-PBMS) model.</p></div><div><h3>Methods</h3><p>Biokinetic data of a radioligand for the Prostate-Specific Membrane Antigen (PSMA) for cancer treatment were used. Eleven fit functions were derived from various parameterisations of mono-, bi-, and tri-exponential functions. The functions' fixed and random effects parameters were fitted (in the NLME framework) to the biokinetic data of all patients. The goodness of fit was assumed acceptable based on the visual inspection of the fitted curves and the coefficients of variation of the fitted fixed effects. The Akaike weight, the probability that the model is the best among the whole set of considered models, was used to select the fit function most supported by the data from the set of functions with acceptable goodness of fit. NLME-PBMS Model Averaging (MA) was performed with all functions having acceptable goodness of fit. The Root-Mean-Square Error (RMSE) of the calculated TIAs from individual-based model selection (IBMS), a shared-parameter population-based model selection (SP-PBMS) reported in the literature, and the functions from NLME-PBMS method to the TIAs from MA were calculated and analysed. The NLME-PBMS (MA) model was used as the reference as this model considers all relevant functions with corresponding Akaike weights.</p></div><div><h3>Results</h3><p>The function <span><math><mrow><msub><mi>f</mi><mrow><mn>3</mn><mi>a</mi></mrow></msub><mo>=</mo><msub><mi>A</mi><mn>1</mn></msub><msup><mrow><mspace></mspace><mi>e</mi></mrow><mrow><mo>-</mo><mfenced><mrow><msub><mi>λ</mi><mn>1</mn></msub><mo>+</mo><msub><mi>λ</mi><mrow><mi>phys</mi></mrow></msub></mrow></mfenced><mi>t</mi></mrow></msup><mo>+</mo><msub><mi>A</mi><mn>2</mn></msub><msup><mrow><mspace></mspace><mi>e</mi></mrow><mrow><mo>-</mo><mfenced><mrow><msub><mi>λ</mi><mrow><mi>phys</mi></mrow></msub></mrow></mfenced><mi>t</mi></mrow></msup></mrow></math></span> was selected as the function most supported by the data with an Akaike weight of (54 ± 11) %. Visual inspection of the fitted graphs and the RMSE values show that the NLME model selection method has a relatively better or equivalent performance than the IBMS or SP-PBMS methods. The RMSEs of the IBMS, SP-PBMS, and NLME-PBMS (<span><math><msub><mi>f</mi><mrow><mn>3</mn><mi>a</mi></mrow></msub></math></span>) methods are 7.4%, 8.8%, and 2.4%, respectively.</p></div><div><h3>Conclusion</h3><p>A procedure including fitting function selection in a population-based method was developed to determine the best fit function for calculating TIAs in MRT for a given radiopharmaceutical, organ and set of biokinetic data. The technique combines standard practice approaches in pharmacokinetics, i.e. an Akaike-weight-based model selection and the NLME model framework.</p></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0939388923000077/pdfft?md5=74c506ab31c26e269984eefabd8f12a8&pid=1-s2.0-S0939388923000077-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0939388923000077\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939388923000077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
摘要
目的:在分子放射治疗(MRT)中,精确确定吸收剂量的个性化治疗计划是非常理想的。吸收剂量是根据时间综合活动(TIA)和剂量转换系数计算得出的。在 MRT 剂量测定中,一个尚未解决的关键问题是在计算 TIA 时应使用哪种拟合函数。基于数据的人群拟合函数选择有助于解决这一问题。因此,本项目旨在开发和评估一种在 MRT 中准确确定 TIA 的方法,该方法在非线性混合效应(NLME-PBMS)模型框架内执行基于人群的模型选择:方法:使用用于治疗癌症的前列腺特异性膜抗原(PSMA)放射性配体的生物动力学数据。通过对单、双和三指数函数的不同参数设置,得出了 11 个拟合函数。这些函数的固定效应和随机效应参数(在 NLME 框架内)与所有患者的生物动力学数据进行了拟合。根据对拟合曲线和拟合固定效应变异系数的目测,假定拟合优度是可以接受的。Akaike 权重是指模型在所有考虑的模型中成为最佳模型的概率,用于从拟合优度可接受的函数集中选择数据最支持的拟合函数。对所有拟合优度可接受的函数进行 NLME-PBMS 模型平均(MA)。计算并分析了基于个体的模型选择(IBMS)、文献中报道的基于共享参数的群体模型选择(SP-PBMS)以及 NLME-PBMS 方法的函数与 MA 的 TIA 计算结果的均方根误差(RMSE)。NLME-PBMS(MA)模型被用作参考,因为该模型考虑了所有相关函数及相应的 Akaike 权重:结果:函数[公式:见正文]被选为数据支持率最高的函数,其 Akaike 权重为 (54 ± 11) %。对拟合图形和均方根误差值的目测表明,NLME 模型选择方法比 IBMS 或 SP-PBMS 方法具有更好或同等的性能。IBMS、SP-PBMS 和 NLME-PBMS (f3a) 方法的均方根误差分别为 7.4%、8.8% 和 2.4%:我们开发了一种基于群体的方法,包括拟合函数选择在内的程序,用于确定计算特定放射性药物、器官和生物动力学数据集的 MRT TIA 的最佳拟合函数。该技术结合了药代动力学的标准实践方法,即基于 Akaike 权重的模型选择和 NLME 模型框架。
Population-based model selection for an accurate estimation of time-integrated activity using non-linear mixed-effects modelling
Purpose
Personalized treatment planning in Molecular Radiotherapy (MRT) with accurately determining the absorbed dose is highly desirable. The absorbed dose is calculated based on the Time-Integrated Activity (TIA) and the dose conversion factor. A crucial unresolved issue in MRT dosimetry is which fit function to use for the TIA calculation. A data-driven population-based fitting function selection could help solve this problem. Therefore, this project aims to develop and evaluate a method for accurately determining TIAs in MRT, which performs a Population-Based Model Selection within the framework of the Non-Linear Mixed-Effects (NLME-PBMS) model.
Methods
Biokinetic data of a radioligand for the Prostate-Specific Membrane Antigen (PSMA) for cancer treatment were used. Eleven fit functions were derived from various parameterisations of mono-, bi-, and tri-exponential functions. The functions' fixed and random effects parameters were fitted (in the NLME framework) to the biokinetic data of all patients. The goodness of fit was assumed acceptable based on the visual inspection of the fitted curves and the coefficients of variation of the fitted fixed effects. The Akaike weight, the probability that the model is the best among the whole set of considered models, was used to select the fit function most supported by the data from the set of functions with acceptable goodness of fit. NLME-PBMS Model Averaging (MA) was performed with all functions having acceptable goodness of fit. The Root-Mean-Square Error (RMSE) of the calculated TIAs from individual-based model selection (IBMS), a shared-parameter population-based model selection (SP-PBMS) reported in the literature, and the functions from NLME-PBMS method to the TIAs from MA were calculated and analysed. The NLME-PBMS (MA) model was used as the reference as this model considers all relevant functions with corresponding Akaike weights.
Results
The function was selected as the function most supported by the data with an Akaike weight of (54 ± 11) %. Visual inspection of the fitted graphs and the RMSE values show that the NLME model selection method has a relatively better or equivalent performance than the IBMS or SP-PBMS methods. The RMSEs of the IBMS, SP-PBMS, and NLME-PBMS () methods are 7.4%, 8.8%, and 2.4%, respectively.
Conclusion
A procedure including fitting function selection in a population-based method was developed to determine the best fit function for calculating TIAs in MRT for a given radiopharmaceutical, organ and set of biokinetic data. The technique combines standard practice approaches in pharmacokinetics, i.e. an Akaike-weight-based model selection and the NLME model framework.